Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View
Abstract
:1. Influenza—Introduction
2. Vaccination Strategies and Currently Licenced Vaccines
3. To Mimic the Natural Immune Response to Influenza—The Goal of Future Vaccines?
4. Adjuvants
5. Safety
6. Challenge: Lack of Knowledge due to Clinical Underdiagnosis of Influenza
7. Our Perspective for the Expectations for Future Influenza Vaccines
8. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Potter, C.W. A history of influenza. J. Appl. Microbiol. 2001, 91, 572–579. [Google Scholar] [CrossRef] [PubMed]
- Iuliano, A.D.; Roguski, K.M.; Chang, H.H.; Muscatello, D.J.; Palekar, R.; Tempia, S.; Cohen, C.; Gran, J.M.; Schanzer, D.; Cowling, B.J.; et al. Estimates of global seasonal influenza-associated respiratory mortality: A modelling study. Lancet 2018, 391, 1285–1300. [Google Scholar] [CrossRef]
- Meltzer, M.I.; Cox, N.J.; Fukuda, K. The economic impact of pandemic influenza in the United States: Priorities for intervention. Emerg. Infect. Dis. 1999, 5, 659–671. [Google Scholar] [CrossRef] [PubMed]
- Molinari, N.A.; Ortega-Sanchez, I.R.; Messonnier, M.L.; Thompson, W.W.; Wortley, P.M.; Weintraub, E.; Bridges, C.B. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 2007, 25, 5086–5096. [Google Scholar] [CrossRef] [PubMed]
- Rothman, T. The cost of influenza disease burden in U.S. Population. Int. J. Econ. Manag. Sci. 2017, 6, 443. [Google Scholar] [CrossRef]
- Wooten, K.G.; Wortley, P.M.; Singleton, J.A.; Euler, G.L. Perceptions matter: Beliefs about influenza vaccine and vaccination behavior among elderly white, black and hispanic americans. Vaccine 2012, 30, 6927–6934. [Google Scholar] [CrossRef] [PubMed]
- Cheney, M.K.; John, R. Underutilization of influenza vaccine:A test of the health belief model. SAGE Open 2013, 3. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention (CDC). People at High Risk of Developing Flu–Related Complications. Available online: https://www.cdc.gov/flu/about/disease/high_risk.htm (accessed on 28 April 2018).
- CDC. Vaccination: Who Should Do It, Who Should Not and Who Should Take Precautions. Available online: https://www.cdc.gov/flu/protect/whoshouldvax.htm (accessed on 20 April 2018).
- Hodgson, D.; Baguelin, M.; van Leeuwen, E.; Panovska-Griffiths, J.; Ramsay, M.; Pebody, R.; Atkins, K.E. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in england and wales: A modelling and cost-effectiveness analysis. Lancet Public Health 2017, 2, e74–e81. [Google Scholar] [CrossRef]
- Heikkinen, T. Influenza in children. Acta Paediatr. 2006, 95, 778–784. [Google Scholar] [CrossRef] [PubMed]
- De Jong, J.C.; Beyer, W.E.; Palache, A.M.; Rimmelzwaan, G.F.; Osterhaus, A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J. Med. Virol. 2000, 61, 94–99. [Google Scholar] [CrossRef]
- Xie, H.; Wan, X.F.; Ye, Z.; Plant, E.P.; Zhao, Y.; Xu, Y.; Li, X.; Finch, C.; Zhao, N.; Kawano, T.; et al. H3N2 mismatch of 2014–15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Sci. Rep. 2015, 5, 15279. [Google Scholar] [CrossRef] [PubMed]
- Skowronski, D.M.; Chambers, C.; De Serres, G.; Dickinson, J.A.; Winter, A.-L.; Hickman, R.; Chan, T.; Jassem, A.N.; Drews, S.J.; Charest, H.; et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): Interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Eurosurveillance 2018, 23. [Google Scholar] [CrossRef] [PubMed]
- Castilla, J.; Navascués, A.; Casado, I.; Pérez-García, A.; Aguinaga, A.; Ezpeleta, G.; Pozo, F.; Ezpeleta, C.; Martínez-Baz, I.; Network, P.H.C.S.; et al. Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza b, northern spain, 2017/18. Eurosurveillance 2018, 23. [Google Scholar] [CrossRef] [PubMed]
- Perdue, M.L.; Arnold, F.; Li, S.; Donabedian, A.; Cioce, V.; Warf, T.; Huebner, R. The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 2011, 10, 1183–1194. [Google Scholar] [CrossRef] [PubMed]
- Tripp, R.A.; Tompkins, S.M. Virus-vectored influenza virus vaccines. Viruses 2014, 6, 3055–3079. [Google Scholar] [CrossRef] [PubMed]
- Kon, T.C.; Onu, A.; Berbecila, L.; Lupulescu, E.; Ghiorgisor, A.; Kersten, G.F.; Cui, Y.-Q.; Amorij, J.-P.; Van der Pol, L. Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes. PLoS ONE 2016, 11, e0150700. [Google Scholar] [CrossRef] [PubMed]
- Wong, S.S.; Webby, R.J. Traditional and new influenza vaccines. Clin. Microbiol. Rev. 2013, 26, 476–492. [Google Scholar] [CrossRef] [PubMed]
- Wilkinson, K.; Wei, Y.; Szwajcer, A.; Rabbani, R.; Zarychanski, R.; Abou-Setta, A.M.; Mahmud, S.M. Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine 2017, 35, 2775–2780. [Google Scholar] [CrossRef] [PubMed]
- Young-Xu, Y.; Van Aalst, R.; Mahmud, S.M.; Rothman, K.J.; Thornton Snider, J.; Westreich, D.; Mor, V.; Gravenstein, S.; Lee, J.K.H.; Thommes, E.W.; et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among veterans health administration patients. J. Infect. Dis. 2018, 217, 1718–1727. [Google Scholar] [CrossRef] [PubMed]
- Woolthuis, R.G.; Wallinga, J.; van Boven, M. Variation in loss of immunity shapes influenza epidemics and the impact of vaccination. BMC Infect. Dis. 2017, 17, 632. [Google Scholar] [CrossRef] [PubMed]
- Carter, N.J.; Curran, M.P. Live attenuated influenza vaccine (Flumist; Fluenz): A review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71, 1591–1622. [Google Scholar] [CrossRef] [PubMed]
- Ambrose, C.S.; Luke, C.; Coelingh, K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir. Viruses 2008, 2, 193–202. [Google Scholar] [CrossRef] [PubMed]
- Cha, T.-A.; Kao, K.; Zhao, J.; Fast, P.E.; Mendelman, P.M.; Arvin, A. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J. Clin. Microbiol. 2000, 38, 839–845. [Google Scholar] [PubMed]
- Cox, M.M.; Patriarca, P.A.; Treanor, J. Flublok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir. Viruses 2008, 2, 211–219. [Google Scholar] [CrossRef] [PubMed]
- Cox, M.M.; Izikson, R.; Post, P.; Dunkle, L. Safety, efficacy, and immunogenicity of flublok in the prevention of seasonal influenza in adults. Ther. Adv. Vaccines 2015, 3, 97–108. [Google Scholar] [CrossRef] [PubMed]
- Cox, R.J. Correlates of protection to influenza virus, where do we go from here? Hum. Vaccines Immunother. 2013, 9, 405–408. [Google Scholar] [CrossRef]
- Andrewes, C.H.; Laidlaw, P.P.; Smith, W. Influenza: Observations on the recovery of virus from man and on the antibody content of human sera. Br. J. Exp. Pathol. 1935, 16, 566–582. [Google Scholar] [CrossRef]
- Clements, M.L.; Murphy, B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J. Clin. Microbiol. 1986, 23, 66–72. [Google Scholar] [PubMed]
- Hobson, D.; Curry, R.L.; Beare, A.S.; Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 1972, 70, 767–777. [Google Scholar] [CrossRef] [PubMed]
- Jefferson, T.; Di Pietrantonj, C.; Rivetti, A.; Bawazeer, G.A.; Al-Ansary, L.A.; Ferroni, E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 2010, Cd001269. [Google Scholar] [CrossRef]
- Surveillance of Influenza and Other Respiratory Infections in the Netherlands: Winter 2014/2015. Available online: https://www.rivm.nl/en/Documents_and_publications/Scientific/Reports/2015/oktober/Surveillance_of_influenza_and_other_respiratory_infections_in_the_Netherlands_winter_2014_2015 (accessed on 20 April 2018).
- Pebody, R.G.; Warburton, F.; Ellis, J.; Andrews, N.; Thompson, C.; von Wissmann, B.; Green, H.K.; Cottrell, S.; Johnston, J.; de Lusignan, S.; et al. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Eurosurveillance 2015, 20, 21025. [Google Scholar] [CrossRef] [PubMed]
- Tisa, V.; Barberis, I.; Faccio, V.; Paganino, C.; Trucchi, C.; Martini, M.; Ansaldi, F. Quadrivalent influenza vaccine: A new opportunity to reduce the influenza burden. J. Prev. Med. Hyg. 2016, 57, E28–E33. [Google Scholar] [PubMed]
- European Centre for Disease Prevention and Control (ECDC). Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively. Eurosurveillance 2018, 23, 18-00146. [Google Scholar]
- Hoft, D.F.; Babusis, E.; Worku, S.; Spencer, C.T.; Lottenbach, K.; Truscott, S.M.; Abate, G.; Sakala, I.G.; Edwards, K.M.; Creech, C.B.; et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse t-cell responses in young children. J. Infect. Dis. 2011, 204, 845–853. [Google Scholar] [CrossRef] [PubMed]
- He, X.S.; Holmes, T.H.; Zhang, C.; Mahmood, K.; Kemble, G.W.; Lewis, D.B.; Dekker, C.L.; Greenberg, H.B.; Arvin, A.M. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 2006, 80, 11756–11766. [Google Scholar] [CrossRef] [PubMed]
- Forrest, B.D.; Pride, M.W.; Dunning, A.J.; Capeding, M.R.; Chotpitayasunondh, T.; Tam, J.S.; Rappaport, R.; Eldridge, J.H.; Gruber, W.C. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol. 2008, 15, 1042–1053. [Google Scholar] [CrossRef] [PubMed]
- Ambrose, C.S.; Wu, X.; Jones, T.; Mallory, R.M. The role of nasal iga in children vaccinated with live attenuated influenza vaccine. Vaccine 2012, 30, 6794–6801. [Google Scholar] [CrossRef] [PubMed]
- Mohn, K.G.; Brokstad, K.A.; Pathirana, R.D.; Bredholt, G.; Jul-Larsen, A.; Trieu, M.C.; Lartey, S.L.; Montemoli, E.; Tondel, C.; Aarstad, H.J.; et al. Live attenuated influenza vaccine in children induces B-cell responses in tonsils. J. Infect. Dis. 2016, 214, 722–731. [Google Scholar] [CrossRef] [PubMed]
- Mohn, K.G.I.; Zhou, F.; Brokstad, K.A.; Sridhar, S.; Cox, R.J. Boosting of cross-reactive and protection-associated t cells in children after live attenuated influenza vaccination. J. Infect. Dis. 2017, 215, 1527–1535. [Google Scholar] [CrossRef] [PubMed]
- Jefferson, T.O.; Rivetti, D.; Di Pietrantonj, C.; Rivetti, A.; Demicheli, V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 2007, Cd001269. [Google Scholar] [CrossRef]
- Jefferson, T.; Rivetti, A.; Harnden, A.; Di Pietrantonj, C.; Demicheli, V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 2008, Cd004879. [Google Scholar] [CrossRef]
- Hayward, A.C.; Wang, L.; Goonetilleke, N.; Fragaszy, E.B.; Bermingham, A.; Copas, A.; Dukes, O.; Millett, E.R.; Nazareth, I.; Nguyen-Van-Tam, J.S.; et al. Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study. Am. J. Respir. Crit. Care Med. 2015, 191, 1422–1431. [Google Scholar] [CrossRef] [PubMed]
- Pebody, R.G.; Green, H.K.; Andrews, N.; Zhao, H.; Boddington, N.; Bawa, Z.; Durnall, H.; Singh, N.; Sunderland, A.; Letley, L.; et al. Uptake and impact of a new live attenuated influenza vaccine programme in england: Early results of a pilot in primary school-age children, 2013/14 influenza season. Eurosurveillance 2014, 19, 20823. [Google Scholar] [CrossRef] [PubMed]
- Glezen, W.P. Universal influenza vaccination and live attenuated influenza vaccination of children. Pediatr. Infect. Dis. J. 2008, 27, S104–S109. [Google Scholar] [CrossRef] [PubMed]
- ACIP Votes Down Use of LAIV for 2016–2017 Flu Season. Available online: https://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html (accessed on 18 April 2018).
- Advisory Committee on Immunization Practices (ACIP) Recommends a Preference for Using the Nasal Spray Flu Vaccine. Available online: https://www.cdc.gov/media/releases/2014/s0625-acip.html (accessed on 18 April 2018).
- Nohynek, H.; Baum, U.; Syrjanen, R.; Ikonen, N.; Sundman, J.; Jokinen, J. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds—A nationwide cohort study finland, influenza season 2015/16. Eurosurveillance 2016, 21, 30346. [Google Scholar] [CrossRef] [PubMed]
- Pebody, R.; Warburton, F.; Ellis, J.; Andrews, N.; Potts, A.; Cottrell, S.; Johnston, J.; Reynolds, A.; Gunson, R.; Thompson, C.; et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Eurosurveillance 2016, 21, 30348. [Google Scholar] [CrossRef] [PubMed]
- Zimmerman, R.K.; Nowalk, M.P.; Chung, J.; Jackson, M.L.; Jackson, L.A.; Petrie, J.G.; Monto, A.S.; McLean, H.Q.; Belongia, E.A.; Gaglani, M.; et al. 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clin. Infect. Dis. 2016, 63, 1564–1573. [Google Scholar] [CrossRef] [PubMed]
- Victor, J.C.; Lewis, K.D.C.; Diallo, A.; Niang, M.N.; Diarra, B.; Dia, N.; Ortiz, J.R.; Widdowson, M.-A.; Feser, J.; Hoagland, R.; et al. Efficacy of a russian-backbone live attenuated influenza vaccine among children in senegal: A randomised, double-blind, placebo-controlled trial. Lancet Glob. Health 2016, 4, e955–e965. [Google Scholar] [CrossRef]
- Brooks, W.A.; Zaman, K.; Lewis, K.D.C.; Ortiz, J.R.; Goswami, D.; Feser, J.; Sharmeen, A.T.; Nahar, K.; Rahman, M.; Rahman, M.Z.; et al. Efficacy of a russian-backbone live attenuated influenza vaccine among young children in Bangladesh: A randomised, double-blind, placebo-controlled trial. Lancet Glob. Health 2016, 4, e946–e954. [Google Scholar] [CrossRef]
- Pebody, R.; Sile, B.; Warburton, F.; Sinnathamby, M.; Tsang, C.; Zhao, H.; Ellis, J.; Andrews, N. Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season. Eurosurveillance 2017, 22, 30450. [Google Scholar] [CrossRef] [PubMed]
- Chung, J.R.; Flannery, B.; Thompson, M.G.; Gaglani, M.; Jackson, M.L.; Monto, A.S.; Nowalk, M.P.; Talbot, H.K.; Treanor, J.J.; Belongia, E.A.; et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics 2016, 137, e20153279. [Google Scholar] [CrossRef] [PubMed]
- ECDC. Seasonal Influenza Vaccines. Available online: https://ecdc.europa.eu/en/seasonal-influenza/facts/factsheet (accessed on 18th April 2018).
- Waffarn, E.E.; Baumgarth, N. Protective B cell responses to flu—No fluke! J. Immunol. 2011, 186, 3823–3829. [Google Scholar] [CrossRef] [PubMed]
- Sasaki, S.; Jaimes, M.C.; Holmes, T.H.; Dekker, C.L.; Mahmood, K.; Kemble, G.W.; Arvin, A.M.; Greenberg, H.B. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J. Virol. 2007, 81, 215–228. [Google Scholar] [CrossRef] [PubMed]
- Huang, K.Y.; Li, C.K.; Clutterbuck, E.; Chui, C.; Wilkinson, T.; Gilbert, A.; Oxford, J.; Lambkin-Williams, R.; Lin, T.Y.; McMichael, A.J.; et al. Virus-specific antibody secreting cell, memory B-cell, and sero-antibody responses in the human influenza challenge model. J. Infect. Dis. 2014, 209, 1354–1361. [Google Scholar] [CrossRef] [PubMed]
- Powers, D.C.; Smith, G.E.; Anderson, E.L.; Kennedy, D.J.; Hackett, C.S.; Wilkinson, B.E.; Volvovitz, F.; Belshe, R.B.; Treanor, J.J. Influenza a virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J. Infect. Dis. 1995, 171, 1595–1599. [Google Scholar] [CrossRef] [PubMed]
- Krammer, F.; Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 2015, 14, 167–182. [Google Scholar] [CrossRef] [PubMed]
- Carter, D.M.; Darby, C.A.; Lefoley, B.C.; Crevar, C.J.; Alefantis, T.; Oomen, R.; Anderson, S.F.; Strugnell, T.; Cortes-Garcia, G.; Vogel, T.U.; et al. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J. Virol. 2016, 90, 4720–4734. [Google Scholar] [CrossRef] [PubMed]
- Carter, D.M.; Darby, C.A.; Johnson, S.K.; Carlock, M.A.; Kirchenbaum, G.A.; Allen, J.D.; Vogel, T.U.; Delagrave, S.; DiNapoli, J.; Kleanthous, H.; et al. Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets preimmune to historical H1N1 influenza viruses. J. Virol. 2017, 91, e01283. [Google Scholar] [CrossRef] [PubMed]
- Wong, T.M.; Allen, J.D.; Bebin-Blackwell, A.G.; Carter, D.M.; Alefantis, T.; DiNapoli, J.; Kleanthous, H.; Ross, T.M. Computationally optimized broadly reactive hemagglutinin elicits hemagglutination inhibition antibodies against a panel of H3N2 influenza virus cocirculating variants. J. Virol. 2017, 91, e01581. [Google Scholar] [CrossRef] [PubMed]
- Nachbagauer, R.; Kinzler, D.; Choi, A.; Hirsh, A.; Beaulieu, E.; Lecrenier, N.; Innis, B.L.; Palese, P.; Mallett, C.P.; Krammer, F. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. NPJ Vaccines 2016, 1, 16015. [Google Scholar] [CrossRef] [PubMed]
- Impagliazzo, A.; Milder, F.; Kuipers, H.; Wagner, M.V.; Zhu, X.; Hoffman, R.M.; van Meersbergen, R.; Huizingh, J.; Wanningen, P.; Verspuij, J.; et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 2015, 349, 1301–1306. [Google Scholar] [CrossRef] [PubMed]
- Yassine, H.M.; Boyington, J.C.; McTamney, P.M.; Wei, C.J.; Kanekiyo, M.; Kong, W.P.; Gallagher, J.R.; Wang, L.; Zhang, Y.; Joyce, M.G.; et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 2015, 21, 1065–1070. [Google Scholar] [CrossRef] [PubMed]
- Valkenburg, S.A.; Mallajosyula, V.V.; Li, O.T.; Chin, A.W.; Carnell, G.; Temperton, N.; Varadarajan, R.; Poon, L.L. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci. Rep. 2016, 6, 22666. [Google Scholar] [CrossRef] [PubMed]
- Sridhar, S.; Begom, S.; Bermingham, A.; Hoschler, K.; Adamson, W.; Carman, W.; Bean, T.; Barclay, W.; Deeks, J.J.; Lalvani, A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 2013, 19, 1305–1312. [Google Scholar] [CrossRef] [PubMed]
- Sridhar, S.; Brokstad, K.A.; Cox, R.J. Influenza vaccination strategies: Comparing inactivated and live attenuated influenza vaccines. Vaccines 2015, 3, 373–389. [Google Scholar] [CrossRef] [PubMed]
- He, X.S.; Holmes, T.H.; Mahmood, K.; Kemble, G.W.; Dekker, C.L.; Arvin, A.M.; Greenberg, H.B. Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J. Infect. Dis. 2008, 197, 803–811. [Google Scholar] [CrossRef] [PubMed]
- Chiu, C.; Openshaw, P.J. Antiviral b cell and T cell immunity in the lungs. Nat. Immunol. 2015, 16, 18–26. [Google Scholar] [CrossRef] [PubMed]
- Sridhar, S.; Begom, S.; Bermingham, A.; Ziegler, T.; Roberts, K.L.; Barclay, W.S.; Openshaw, P.; Lalvani, A. Predominance of heterosubtypic ifn-gamma-only-secreting effector memory t cells in pandemic H1N1 naive adults. Eur. J. Immunol. 2012, 42, 2913–2924. [Google Scholar] [CrossRef] [PubMed]
- Bonduelle, O.; Carrat, F.; Luyt, C.E.; Leport, C.; Mosnier, A.; Benhabiles, N.; Krivine, A.; Rozenberg, F.; Yahia, N.; Samri, A.; et al. Characterization of pandemic influenza immune memory signature after vaccination or infection. J. Clin. Investig. 2014, 124, 3129–3136. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Abbas, A.K.; Lichtman, A.H.; Pillai, S. Cellular and Molecular Immunology, 9th ed.; Elsevier: New York, NY, USA, 2017. [Google Scholar]
- Lanzavecchia, A.; Sallusto, F. Understanding the generation and function of memory T cell subsets. Curr. Opin. Immunol. 2005, 17, 326–332. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Wan, Y.; Qiu, C.; Quinones-Parra, S.; Zhu, Z.; Loh, L.; Tian, D.; Ren, Y.; Hu, Y.; Zhang, X.; et al. Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8(+) T cells. Nat. Commun. 2015, 6, 6833. [Google Scholar] [CrossRef] [PubMed]
- Schulman, J.L.; Kilbourne, E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus. J. Bacteriol. 1965, 89, 170–174. [Google Scholar] [PubMed]
- Slepushkin, A.N. The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. Bull. World Health Organ. 1959, 20, 297–301. [Google Scholar] [PubMed]
- Biddison, W.E.; Shaw, S.; Nelson, D.L. Virus specificity of human influenza virus-immune cytotoxic T cells. J. Immunol. 1979, 122, 660–664. [Google Scholar] [PubMed]
- Lee, P.S.; Yoshida, R.; Ekiert, D.C.; Sakai, N.; Suzuki, Y.; Takada, A.; Wilson, I.A. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc. Natl. Acad. Sci. USA 2012, 109, 17040–17045. [Google Scholar] [CrossRef] [PubMed]
- Benjamin, E.; Wang, W.; McAuliffe, J.M.; Palmer-Hill, F.J.; Kallewaard, N.L.; Chen, Z.; Suzich, J.A.; Blair, W.S.; Jin, H.; Zhu, Q. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J. Virol. 2014, 88, 6743–6750. [Google Scholar] [CrossRef] [PubMed]
- Boonsathorn, N.; Panthong, S.; Koksunan, S.; Chittaganpitch, M.; Phuygun, S.; Waicharoen, S.; Prachasupap, A.; Sasaki, T.; Kubota-Koketsu, R.; Yasugi, M.; et al. A human monoclonal antibody derived from a vaccinated volunteer recognizes heterosubtypically a novel epitope on the hemagglutinin globular head of H1 and H9 influenza a viruses. Biochem. Biophys. Res. Commun. 2014, 452, 865–870. [Google Scholar] [CrossRef] [PubMed]
- Yewdell, J.W.; Bennink, J.R.; Smith, G.L.; Moss, B. Influenza a virus nucleoprotein is a major target antigen for cross-reactive anti-influenza a virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 1985, 82, 1785–1789. [Google Scholar] [CrossRef] [PubMed]
- Gotch, F.; McMichael, A.; Smith, G.; Moss, B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 1987, 165, 408–416. [Google Scholar] [CrossRef] [PubMed]
- Scheible, K.; Zhang, G.; Baer, J.; Azadniv, M.; Lambert, K.; Pryhuber, G.; Treanor, J.J.; Topham, D.J. CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine 2011, 29, 2159–2168. [Google Scholar] [CrossRef] [PubMed]
- Jameson, J.; Cruz, J.; Ennis, F.A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J. Virol. 1998, 72, 8682–8689. [Google Scholar] [PubMed]
- Agrati, C.; Castilletti, C.; Cimini, E.; Lapa, D.; Quartu, S.; Caglioti, C.; Lanini, S.; Cattoli, G.; Martini, F.; Ippolito, G.; et al. Cellular and humoral cross-immunity against two H3N2V influenza strains in presumably unexposed healthy and hiv-infected subjects. PLoS ONE 2014, 9, e105651. [Google Scholar] [CrossRef] [PubMed]
- Lee, L.Y.; Ha do, L.A.; Simmons, C.; de Jong, M.D.; Chau, N.V.; Schumacher, R.; Peng, Y.C.; McMichael, A.J.; Farrar, J.J.; Smith, G.L.; et al. Memory t cells established by seasonal human influenza a infection cross-react with avian influenza a (H5N1) in healthy individuals. J. Clin. Investig. 2008, 118, 3478–3490. [Google Scholar] [CrossRef] [PubMed]
- Quinones-Parra, S.; Grant, E.; Loh, L.; Nguyen, T.H.; Campbell, K.A.; Tong, S.Y.; Miller, A.; Doherty, P.C.; Vijaykrishna, D.; Rossjohn, J.; et al. Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc. Natl. Acad. Sci. USA 2014, 111, 1049–1054. [Google Scholar] [CrossRef] [PubMed]
- Schotsaert, M.; Ysenbaert, T.; Smet, A.; Schepens, B.; Vanderschaeghe, D.; Stegalkina, S.; Vogel, T.U.; Callewaert, N.; Fiers, W.; Saelens, X. Long-lasting cross-protection against influenza A by neuraminidase and M2E-based immunization strategies. Sci. Rep. 2016, 6, 24402. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Antrobus, R.D.; Coughlan, L.; Berthoud, T.K.; Dicks, M.D.; Hill, A.V.; Lambe, T.; Gilbert, S.C. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol. Ther. 2014, 22, 668–674. [Google Scholar] [CrossRef] [PubMed]
- Berthoud, T.K.; Hamill, M.; Lillie, P.J.; Hwenda, L.; Collins, K.A.; Ewer, K.J.; Milicic, A.; Poyntz, H.C.; Lambe, T.; Fletcher, H.A.; et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, MVA-NP+M1. Clin. Infect. Dis. 2011, 52, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Braucher, D.R.; Henningson, J.N.; Loving, C.L.; Vincent, A.L.; Kim, E.; Steitz, J.; Gambotto, A.A.; Kehrli, M.E., Jr. Intranasal vaccination with replication-defective adenovirus type 5 encoding influenza virus hemagglutinin elicits protective immunity to homologous challenge and partial protection to heterologous challenge in pigs. Clin. Vaccine Immunol. 2012, 19, 1722–1729. [Google Scholar] [CrossRef] [PubMed]
- Gomez, C.E.; Najera, J.L.; Krupa, M.; Perdiguero, B.; Esteban, M. MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr. Gene Ther. 2011, 11, 189–217. [Google Scholar] [CrossRef] [PubMed]
- Antrobus, R.D.; Berthoud, T.K.; Mullarkey, C.E.; Hoschler, K.; Coughlan, L.; Zambon, M.; Hill, A.V.; Gilbert, S.C. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol. Ther. 2014, 22, 233–238. [Google Scholar] [CrossRef] [PubMed]
- Le Bon, A.; Schiavoni, G.; D’Agostino, G.; Gresser, I.; Belardelli, F.; Tough, D.F. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14, 461–470. [Google Scholar] [CrossRef]
- Arakawa, T. Adjuvants: No longer a ‘dirty little secret’, but essential key players in vaccines of the future. Expert Rev. Vaccines 2011, 10, 1–5. [Google Scholar] [CrossRef] [PubMed]
- Broadbent, A.J.; Subbarao, K. Influenza virus vaccines: Lessons from the 2009 H1N1 pandemic. Curr. Opin. Virol. 2011, 1, 254–262. [Google Scholar] [CrossRef] [PubMed]
- Reed, S.G.; Orr, M.T.; Fox, C.B. Key roles of adjuvants in modern vaccines. Nat. Med. 2013, 19, 1597–1608. [Google Scholar] [CrossRef] [PubMed]
- Di Pasquale, A.; Preiss, S.; Da Silva, F.T.; Garcon, N. Vaccine adjuvants: From 1920 to 2015 and beyond. Vaccines 2015, 3, 320–343. [Google Scholar] [CrossRef] [PubMed]
- Morel, S.; Didierlaurent, A.; Bourguignon, P.; Delhaye, S.; Baras, B.; Jacob, V.; Planty, C.; Elouahabi, A.; Harvengt, P.; Carlsen, H.; et al. Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29, 2461–2473. [Google Scholar] [CrossRef] [PubMed]
- Vesikari, T.; Pepin, S.; Kusters, I.; Hoffenbach, A.; Denis, M. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum. Vaccines Immunother. 2012, 8, 1283–1292. [Google Scholar] [CrossRef] [PubMed]
- Galson, J.D.; Truck, J.; Kelly, D.F.; van der Most, R. Investigating the effect of AS03 adjuvant on the plasma cell repertoire following PH1N1 influenza vaccination. Sci. Rep. 2016, 6, 37229. [Google Scholar] [CrossRef] [PubMed]
- Domnich, A.; Arata, L.; Amicizia, D.; Puig-Barbera, J.; Gasparini, R.; Panatto, D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine 2017, 35, 513–520. [Google Scholar] [CrossRef] [PubMed]
- Ohmit, S.E.; Victor, J.C.; Rotthoff, J.R.; Teich, E.R.; Truscon, R.K.; Baum, L.L.; Rangarajan, B.; Newton, D.W.; Boulton, M.L.; Monto, A.S. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N. Engl. J. Med. 2006, 355, 2513–2522. [Google Scholar] [CrossRef] [PubMed]
- Bridges, C.B.; Thompson, W.W.; Meltzer, M.I.; Reeve, G.R.; Talamonti, W.J.; Cox, N.J.; Lilac, H.A.; Hall, H.; Klimov, A.; Fukuda, K. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000, 284, 1655–1663. [Google Scholar] [CrossRef] [PubMed]
- Nichol, K.L.; Lind, A.; Margolis, K.L.; Murdoch, M.; McFadden, R.; Hauge, M.; Magnan, S.; Drake, M. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 1995, 333, 889–893. [Google Scholar] [CrossRef] [PubMed]
- Lancet, T. Addressing decreasing vaccine coverage in the EU. Lancet 2018, 391, 1638. [Google Scholar] [CrossRef]
- King, C.; Leask, J. The impact of a vaccine scare on parental views, trust and information needs: A qualitative study in Sydney, Australia. BMC Public Health 2017, 17, 106. [Google Scholar] [CrossRef] [PubMed]
- Blyth, C.C.; Jacoby, P.; Effler, P.V.; Kelly, H.; Smith, D.W.; Robins, C.; Willis, G.A.; Levy, A.; Keil, A.D.; Richmond, P.C. Effectiveness of trivalent flu vaccine in healthy young children. Pediatrics 2014, 133, e1218. [Google Scholar] [CrossRef] [PubMed]
- Nohynek, H.; Jokinen, J.; Partinen, M.; Vaarala, O.; Kirjavainen, T.; Sundman, J.; Himanen, S.L.; Hublin, C.; Julkunen, I.; Olsen, P.; et al. AS03 adjuvanted ah1n1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7, e33536. [Google Scholar] [CrossRef] [PubMed]
- The MPA Investigates Reports of Narcolepsy in Patients Vaccinated with Pandemrix. Available online: https://lakemedelsverket.se/english/All-news/NYHETER-2010/The-MPA-investigates-reports-of-narcolepsy-in-patients-vaccinated-with-Pandemrix/2010 (accessed on 20 April 2018).
- Stowe, J.; Andrews, N.; Kosky, C.; Dennis, G.; Eriksson, S.; Hall, A.; Leschziner, G.; Reading, P.; Shneerson, J.M.; Donegan, K.; et al. Risk of narcolepsy after AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in adults: A case-coverage study in england. Sleep 2016, 39, 1051–1057. [Google Scholar] [CrossRef] [PubMed]
- O’Flanagan, D.; Barret, A.S.; Foley, M.; Cotter, S.; Bonner, C.; Crowe, C.; Lynch, B.; Sweeney, B.; Johnson, H.; McCoy, B.; et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009–December 2010. Eurosurveillance 2014, 19, 20789. [Google Scholar] [CrossRef] [PubMed]
- Partinen, M.; Saarenpää-Heikkilä, O.; Ilveskoski, I.; Hublin, C.; Linna, M.; Olsén, P.; Nokelainen, P.; Alén, R.; Wallden, T.; Espo, M.; et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 2012, 7, e33723. [Google Scholar] [CrossRef] [PubMed]
- Miller, E.; Andrews, N.; Stellitano, L.; Stowe, J.; Winstone, A.M.; Shneerson, J.; Verity, C. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: Retrospective analysis. Br. Med. J. 2013, 346, f794. [Google Scholar] [CrossRef] [PubMed]
- Duffy, J.; Weintraub, E.; Vellozzi, C.; DeStefano, F.; Vaccine Safety, D. Narcolepsy and influenza A(H1N1) pandemic 2009 vaccination in the United States. Neurology 2014, 83, 1823–1830. [Google Scholar] [CrossRef] [PubMed]
- Jorgensen, P.; Mereckiene, J.; Cotter, S.; Johansen, K.; Tsolova, S.; Brown, C. How close are countries of the who european region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. Vaccine 2018, 36, 442–452. [Google Scholar] [CrossRef] [PubMed]
- CDC. Rapid Influenza Diagnostic Tests. Available online: https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm (accessed on 20 April 2018).
- Krammer, F. The quest for a universal flu vaccine: Headless HA 2.0. Cell Host Microbe 2015, 18, 395–397. [Google Scholar] [CrossRef] [PubMed]
- Mohn, K.G.; Bredholt, G.; Brokstad, K.A.; Pathirana, R.D.; Aarstad, H.J.; Tondel, C.; Cox, R.J. Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. J. Infect. Dis. 2015, 211, 1541–1549. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ilyushina, N.A.; Haynes, B.C.; Hoen, A.G.; Khalenkov, A.M.; Housman, M.L.; Brown, E.P.; Ackerman, M.E.; Treanor, J.J.; Luke, C.J.; Subbarao, K.; et al. Live attenuated and inactivated influenza vaccines in children. J. Infect. Dis. 2015, 211, 352–360. [Google Scholar] [CrossRef] [PubMed]
- Fisman, D.N.; Bogoch, I.I. Have you herd? Indirect flu vaccine effects are critically important. Lancet Public Health 2017, 2, e57–e58. [Google Scholar] [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mohn, K.G.-I.; Zhou, F. Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View. Vaccines 2018, 6, 32. https://doi.org/10.3390/vaccines6020032
Mohn KG-I, Zhou F. Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View. Vaccines. 2018; 6(2):32. https://doi.org/10.3390/vaccines6020032
Chicago/Turabian StyleMohn, Kristin G.-I., and Fan Zhou. 2018. "Clinical Expectations for Better Influenza Virus Vaccines—Perspectives from the Young Investigators’ Point of View" Vaccines 6, no. 2: 32. https://doi.org/10.3390/vaccines6020032